[
  {
    "ts": null,
    "headline": "Biogen Inc. stock outperforms competitors on strong trading day",
    "summary": "Biogen Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=38ebe9b2ebd2b4a28b60bc9027eec3e0ca5835477b742c61d3b6a8f3920022d4",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759511100,
      "headline": "Biogen Inc. stock outperforms competitors on strong trading day",
      "id": 137025364,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Biogen Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=38ebe9b2ebd2b4a28b60bc9027eec3e0ca5835477b742c61d3b6a8f3920022d4"
    }
  },
  {
    "ts": null,
    "headline": "ImmunityBio: A Small Bet Is Warranted",
    "summary": "ImmunityBio offers significant upside despite ongoing dilution and cash burn concerns. Click here to read an analysis of IBRX stock now.",
    "url": "https://finnhub.io/api/news?id=79b8a7a844b648e07083bde5435ae809c7946248f4d405f7e408dd5db381d5d6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759497864,
      "headline": "ImmunityBio: A Small Bet Is Warranted",
      "id": 136966013,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2167417147/image_2167417147.jpg?io=getty-c-w1536",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "ImmunityBio offers significant upside despite ongoing dilution and cash burn concerns. Click here to read an analysis of IBRX stock now.",
      "url": "https://finnhub.io/api/news?id=79b8a7a844b648e07083bde5435ae809c7946248f4d405f7e408dd5db381d5d6"
    }
  },
  {
    "ts": null,
    "headline": "Is Global Expansion of LEQEMBI Enough to Reinforce Biogen’s (BIIB) Long-Term Pipeline Strength?",
    "summary": "Eisai Co., Ltd. and Biogen Inc. recently announced that Australia’s Therapeutic Goods Administration approved LEQEMBI (lecanemab) for use in adults with mild cognitive impairment or mild dementia due to Alzheimer’s disease, supported by positive Phase 3 Clarity AD trial data. This marks another key regulatory milestone that expands LEQEMBI’s international reach, as new dosing options gain approval in countries including China and the US, potentially making Alzheimer’s treatment more...",
    "url": "https://finnhub.io/api/news?id=76f10b3d7abb7cafe2e7e6173e93c3e0a61a3c15e455e01a98a4776ff770fd9a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759491608,
      "headline": "Is Global Expansion of LEQEMBI Enough to Reinforce Biogen’s (BIIB) Long-Term Pipeline Strength?",
      "id": 136964519,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Eisai Co., Ltd. and Biogen Inc. recently announced that Australia’s Therapeutic Goods Administration approved LEQEMBI (lecanemab) for use in adults with mild cognitive impairment or mild dementia due to Alzheimer’s disease, supported by positive Phase 3 Clarity AD trial data. This marks another key regulatory milestone that expands LEQEMBI’s international reach, as new dosing options gain approval in countries including China and the US, potentially making Alzheimer’s treatment more...",
      "url": "https://finnhub.io/api/news?id=76f10b3d7abb7cafe2e7e6173e93c3e0a61a3c15e455e01a98a4776ff770fd9a"
    }
  },
  {
    "ts": null,
    "headline": "Novartis: Superstars Entresto And Kisqali Fuel Market Outperformance",
    "summary": "Novartis shines with oncology growth, strong buybacks, and a $1.4B heart drug acquisition, defying headwinds like Entresto generics. Read why NVS stock is a buy.",
    "url": "https://finnhub.io/api/news?id=19544720167cb57ffae0079873d350c27432d55c7a1bc442759b979b242ebbe6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759481800,
      "headline": "Novartis: Superstars Entresto And Kisqali Fuel Market Outperformance",
      "id": 136964031,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1304608112/image_1304608112.jpg?io=getty-c-w1536",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "Novartis shines with oncology growth, strong buybacks, and a $1.4B heart drug acquisition, defying headwinds like Entresto generics. Read why NVS stock is a buy.",
      "url": "https://finnhub.io/api/news?id=19544720167cb57ffae0079873d350c27432d55c7a1bc442759b979b242ebbe6"
    }
  }
]